首页> 中文期刊> 《中国药房》 >组蛋白去乙酰化酶抑制剂RGFP109逆转胶质母细胞瘤U251细胞对替莫唑胺耐药性的机制研究

组蛋白去乙酰化酶抑制剂RGFP109逆转胶质母细胞瘤U251细胞对替莫唑胺耐药性的机制研究

         

摘要

OBJECTIVE:To study the mechanism of histone deacetylase inhibitor RGFP109 in reversing resistance of glioma U251 cells. METHODS:TR/U251 cells resistance to temozolomide(TMZ)was extrablished. The test was divided into normal con-trol group,TMZ group(40 μmol/L)and TMZ(40 μmol/L)+RGFP109(0-120 μmol/L)different concentrations groups. After 24 h of adding into related medicines,CCK-8 was used to detect the cell survival rate and calculate the half inhibitory concentration (IC50). TUNEL and Annexin V/PI were used to detect the cell apoptosis in normal control group,TMZ group and TMZ+RGFP109 (42μmol/L)group. Immunoblotting was used to detect the O6-methyl guanine-DNA methyltransferase(MGMT),Survivin,B lym-phoma 2(Bcl-2),B lymphoma xL(Bcl-xL)protein expression;and gel migration test was used to detect the p65 acetylation level and its binding capacity with κB-DNA. RESULTS:Compared with normal control group,cell survival rate in TMZ+RGFP109 dif-ferent concentrations groups was obviously decreased (P<0.05),showing a concentration-dependent manner. When the RGFP109 concentration was 42 μmol/L,the sensitivity of TMZ to TR/U251 cells was the same with U251 cells. Compared with normal con-trol group,MGMT,Survivin,Bcl-2,Bcl-xL protein expressions in cells of TMZ groups were enhanced(P<0.01);p65 acetyla-tion level had no obvious changes,while the binding capacity of p65 and κB-DNA was strengthened (P<0.01). Compared with TMZ group,MGMT,Survivin,Bcl-2,Bcl-xL protein expressions in cells of TMZ groups were weakened(P<0.01);p65 acetyla-tion level was enhanced (P<0.01);and the binding capacity of p65 and κB-DNA was weakened (P<0.01). CONCLUSIONS:RGFP109 can reverse the resistance of U251 cells to TMZ by down-regulating the anti-apoptotic protein expressions adjusted by transcription factorκB(NF-κB)and weakening the binding of p65 andκB-DNA.%目的:研究组蛋白去乙酰化酶抑制剂RGFP109逆转胶质母细胞瘤U251细胞的耐药性机制.方法:建立对替莫唑胺(TMZ)耐药的TR/U251细胞,试验分为正常对照组、TMZ组(40μmol/L)和TMZ(40μmol/L)+RGFP109(0~120μmol/L)不同浓度组,加入相应药物作用24 h后,CCK-8法检测细胞存活率,计算半数抑制浓度(IC50).TUNEL法和Annexin V/PI法检测正常对照组、TMZ组和TMZ+RGFP109(42μmol/L)组细胞的凋亡情况,免疫印迹法检测3组细胞中O6-甲基鸟嘌呤-DNA甲基转移酶(MG-MT)、存活蛋白(Survivin)、B淋巴细胞瘤2(Bcl-2)、B淋巴细胞瘤xL(Bcl-xL)蛋白表达,凝胶迁移实验检测3组细胞中p65乙酰化水平及其与κB-DNA的结合能力.结果:与正常对照组和TMZ组比较,TMZ+RGFP109不同浓度组细胞存活率明显降低(P<0.05),且呈浓度依赖性.当RGFP109浓度为42μmol/L时,TMZ对TR/U251细胞的敏感性与U251细胞相同.与正常对照组比较,TMZ组细胞中MGMT、Survivin、Bcl-2、Bcl-xL蛋白表达均增强(P<0.01),p65乙酰化水平无明显变化,但p65与κB-DNA的结合能力增强(P<0.01).与TMZ组比较,TMZ+RGFP109组细胞中MGMT、Survivin、Bcl-2、Bcl-xL蛋白表达均减弱(P<0.01),p65乙酰化水平增强(P<0.01),p65与κB-DNA的结合能力减弱(P<0.01).结论:RGFP109可通过下调转录因子κB调节的抗凋亡蛋白表达,减弱p65与κB-DNA的结合来逆转U251细胞对TMZ耐药.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号